Nattokinase

Moderate evidence for fibrinolytic activity and blood pressure reduction. One of the better-studied fibrinolytic enzymes with a long history of safe use in Japan.

A rough internal score reflecting quantity, quality, and consistency of human evidence. Not a clinical recommendation.

Nattokinase degrades fibrin directly and enhances endogenous fibrinolysis by increasing tissue plasminogen activator. A meta-analysis of RCTs found significant blood pressure reduction (~5-7 mmHg systolic). It also reduces blood viscosity and may lower LDL cholesterol. Widely consumed in Japan with a long safety record.

• Degrades fibrin and reduces blood viscosity
• Modest blood pressure reduction in meta-analyses
• Long safety history in Japanese dietary tradition

Typical dose: 2000-4000 FU (fibrinolysis units) daily, equivalent to approximately 100-200 mg. Take on empty stomach for best absorption.

• Increased bleeding risk
• GI discomfort
• Rare allergic reactions (soy-derived)

Contraindicated with anticoagulants. Discontinue 2 weeks before surgery. Avoid with bleeding disorders. Soy-derived; not suitable for severe soy allergy.

Fibrinolytic activity is demonstrated, but clinical cardiovascular outcome data (MI, stroke prevention) from RCTs is absent. Blood pressure effects are modest. Product standardization (in FU units) varies.

• Longevity45